Everything tagged "fda approval" across research, earnings, and macro.
2 articles
Biogen’s selloff looks backward-looking. A newly approved home-start LEQEMBI formulation and fresh real-world stability data make the Alzheimer’s story easier to scale, not harder to believe.
Ionis got hit as if the Wainua trial miss broke the whole equity story, and that looks too simplistic. The bigger near-term driver is now TRYNGOLZA's expanded launch, with commercial revenue already up 42% and management raising its olezarsen peak-sales view above $3 billion.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator